Stock listing
NASDAQ:ADAG Adagene, Inc. Stock
Follow Adagene, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ADAG
$1.76 USD -0.06 (-3.3%)
Close on Nov 20, 2026
- Day range
- $1.35 – $2.05 USDNov 20, 2026
- Volume
- 1.37M sharesNov 20, 2026
- Market cap
- $118.2M USDAt the close on Nov 20, 2026 · price × 67.14M shares outstanding
- 52-week range
- $1.27 – $4.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $824,939 USDMedian day 216,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ADAG · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.76 | -0.06 | -3.3% | $2.00 | $2.05 | $1.35 | 1,371,420 | |
| $1.82 | +0.34 | +23.0% | $1.48 | $1.95 | $1.48 | 1,295,036 | |
| $1.48 | -0.12 | -7.5% | $1.51 | $1.82 | $1.267 | 2,338,431 | |
| $1.60 | -0.11 | -6.4% | $1.77 | $1.85 | $1.418 | 945,089 | |
| $1.71 | -0.29 | -14.5% | $1.96 | $1.96 | $1.70 | 152,058 | |
| $2.00 | -0.13 | -6.1% | $2.16 | $2.28 | $1.91 | 278,107 | |
| $2.13 | +0.08 | +3.9% | $2.036 | $2.42 | $1.96 | 222,126 | |
| $2.05 | -0.07 | -3.3% | $2.12 | $2.14 | $2.01 | 85,678 | |
| $2.12 | +0.12 | +6.0% | $2.10 | $2.27 | $2.08 | 158,551 | |
| $2.00 | -0.02 | -1.0% | $2.11 | $2.19 | $1.93 | 189,025 | |
| $2.02 | -0.39 | -16.2% | $2.24 | $2.24 | $2.005 | 345,328 | |
| $2.41 | +0.06 | +2.6% | $2.49 | $2.52 | $2.34 | 114,829 | |
| $2.35 | +0.06 | +2.6% | $2.25 | $2.535 | $2.25 | 107,351 | |
| $2.29 | -0.22 | -8.8% | $2.52 | $2.54 | $2.17 | 181,777 | |
| $2.51 | -0.17 | -6.3% | $2.67 | $2.69 | $2.46 | 79,571 | |
| $2.68 | +0.01 | +0.4% | $2.72 | $2.72 | $2.60 | 172,571 | |
| $2.67 | +0.09 | +3.5% | $2.75 | $2.78 | $2.61 | 235,602 | |
| $2.58 | +0.09 | +3.6% | $2.625 | $2.67 | $2.44 | 189,230 | |
| $2.49 | +0.08 | +3.3% | $2.42 | $2.55 | $2.34 | 91,197 | |
| $2.41 | -0.03 | -1.2% | $2.42 | $2.57 | $2.295 | 167,165 | |
| $2.44 | +0.03 | +1.2% | $2.385 | $2.50 | $2.275 | 244,219 | |
| $2.41 | -0.09 | -3.6% | $2.55 | $2.55 | $2.39 | 95,527 | |
| $2.50 | +0.21 | +9.2% | $2.30 | $2.50 | $2.30 | 86,627 | |
| $2.29 | +0.23 | +11.2% | $2.04 | $2.29 | $2.01 | 306,389 | |
| $2.06 | -0.34 | -14.2% | $2.40 | $2.40 | $2.01 | 379,601 | |
| $2.40 | +0.11 | +4.8% | $2.31 | $2.42 | $2.26 | 552,483 | |
| $2.29 | -0.17 | -6.9% | $2.35 | $2.50 | $2.25 | 898,863 | |
| $2.46 | -0.28 | -10.2% | $2.73 | $2.73 | $2.435 | 228,500 | |
| $2.74 | -0.02 | -0.7% | $2.77 | $2.855 | $2.68 | 216,500 | |
| $2.76 | -0.02 | -0.7% | $2.76 | $2.87 | $2.625 | 1,649,300 | |
| $2.78 | -0.03 | -1.1% | $2.80 | $3.10 | $2.71 | 240,500 | |
| $2.81 | -0.12 | -4.1% | $2.90 | $3.102 | $2.785 | 173,100 | |
| $2.93 | +0.13 | +4.6% | $2.82 | $3.02 | $2.82 | 213,500 | |
| $2.80 | -0.05 | -1.8% | $2.84 | $2.87 | $2.67 | 325,700 | |
| $2.85 | -0.08 | -2.7% | $2.96 | $3.00 | $2.80 | 298,000 | |
| $2.93 | -0.27 | -8.4% | $3.12 | $3.12 | $2.915 | 278,300 | |
| $3.20 | -0.01 | -0.3% | $3.18 | $3.35 | $3.00 | 254,300 | |
| $3.21 | +0.01 | +0.3% | $3.20 | $3.47 | $2.98 | 492,300 | |
| $3.20 | +0.27 | +9.2% | $2.94 | $3.21 | $2.87 | 528,400 | |
| $2.93 | -0.05 | -1.7% | $2.96 | $3.185 | $2.87 | 196,900 | |
| $2.98 | +0.01 | +0.3% | $2.94 | $3.01 | $2.81 | 317,000 | |
| $2.97 | -0.26 | -8.0% | $3.16 | $3.22 | $2.92 | 208,000 | |
| $3.23 | +0.02 | +0.6% | $3.31 | $3.338 | $3.215 | 226,300 | |
| $3.21 | -0.10 | -3.0% | $3.34 | $3.35 | $3.18 | 97,800 | |
| $3.31 | -0.06 | -1.8% | $3.37 | $3.505 | $3.171 | 287,000 | |
| $3.37 | +0.20 | +6.3% | $3.30 | $3.419 | $3.17 | 260,600 | |
| $3.17 | +0.20 | +6.7% | $3.00 | $3.237 | $2.92 | 319,300 | |
| $2.97 | -0.30 | -9.2% | $3.385 | $3.385 | $2.925 | 626,100 | |
| $3.27 | -0.13 | -3.8% | $3.38 | $3.60 | $3.235 | 155,100 | |
| $3.40 | +0.09 | +2.7% | $3.36 | $3.48 | $3.239 | 258,600 | |
| $3.31 | +0.04 | +1.2% | $3.54 | $3.552 | $3.20 | 224,500 | |
| $3.27 | -0.22 | -6.3% | $3.61 | $3.69 | $3.24 | 267,500 | |
| $3.49 | -0.09 | -2.5% | $3.55 | $3.61 | $3.45 | 193,000 | |
| $3.58 | -0.11 | -3.0% | $3.67 | $3.692 | $3.56 | 28,100 | |
| $3.69 | 0.00 | 0.0% | $3.71 | $3.85 | $3.56 | 167,700 | |
| $3.69 | +0.05 | +1.4% | $3.60 | $3.74 | $3.60 | 102,700 | |
| $3.64 | +0.13 | +3.7% | $3.51 | $3.675 | $3.42 | 120,500 | |
| $3.51 | -0.17 | -4.6% | $3.62 | $3.62 | $3.451 | 131,600 | |
| $3.68 | -0.22 | -5.6% | $3.89 | $3.89 | $3.66 | 123,200 | |
| $3.90 | +0.05 | +1.3% | $3.85 | $3.97 | $3.71 | 296,200 | |
| $3.85 | +0.03 | +0.8% | $3.97 | $4.09 | $3.82 | 122,000 | |
| $3.82 | -0.08 | -2.1% | $3.90 | $3.97 | $3.80 | 63,072 | |
| $3.90 | -0.12 | -3.0% | $3.99 | $4.005 | $3.795 | 159,180 | |
| $4.02 | -0.07 | -1.7% | $4.11 | $4.115 | $3.97 | 61,300 | |
| $4.09 | -0.03 | -0.7% | $4.11 | $4.18 | $4.01 | 205,000 |
- Ticker
- NASDAQ:ADAG
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 34 slides
Latest news
Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Nov 19, 2026
Closed $1.76 (-3.3%) on Nov 20, 2026
Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
Nov 17, 2026
Closed $1.48 (-7.5%) on Nov 17, 2026
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Nov 9, 2026
Closed $2.12 (+6.0%) on Nov 9, 2026
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Oct 28, 2026
Closed $2.67 (+3.5%) on Oct 28, 2026
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Oct 27, 2026
Closed $2.58 (+3.6%) on Oct 27, 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Apr 2, 2026
Closed $3.99 (-13.4%) on Apr 2, 2026
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Dec 16, 2025
Closed $1.90 (+13.8%) on Dec 16, 2025
Adagene, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 10 in all · newest Nov 19, 2026 · oldest 2025
- Decks
- 3 decks · latest September 2026
Valuation
EV/sales −0.5× against a median of 13.6×: 2nd lowest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.65M USD
- P/E
- Loss
- EV/sales
- −0.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.1×
- Gross margin
- 100.0%
- Operating margin
- −279.5%
- Net margin
- −229.6%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.43
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.24M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| STCube, Inc. · KRX:052020 | US$118.4M | US$72.43M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Curacle Co., Ltd. · KRX:365270 | US$117.6M | US$100.4M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.97M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| Median of the others | US$118.4M | US$62.60M | 13.6× | 2.5× | −214.8% | 0.0× | 1.29 |
Forecasts
6 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.91 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.51 · 5 analysts
- Revenue, year to Dec 2026
- 1.96M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Peter Luo | Chairman of the Board of Directors |
| Man Kin Tam | Chief Financial Officer |
| Alexander Goergen | Vice President, Head of Business Development |
| Guizhong Liu | Senior Vice President of Early Drug Discovery |
| Jiping Zha | Executive Vice President, Clinical Development |
| Kristine She | Senior Vice President, Head of Clinical Operations |
| Songmao Zheng | Senior Vice President of Clinical Pharmacology and Quantitative Sciences |
| Wenlin Zeng | Vice President of Early Stage CMC |
| Yan Li | Senior Vice President, Bioinformatics and Information Technology |
| Ling Zhou | Executive Director, Head of Human Resources |
| Mickael Chane-Du | Chief Strategy Officer |
| Qinghai Zhao | Chief Manufacturing Officer |
Board
| Director | Role |
|---|---|
| Peter Luo | Chairman of the Board of Directors |
| Andy Cheung | Independent Director |
| Cuong Do | Independent Director |
| Ling Zhou | Executive Director, Head of Human Resources |
| Man Kin Tam | Chief Financial Officer |
| Ulf Grawunder | Independent Director |
| Zhu Li | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | Apr 1, 2026 | +1.8% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −1.0% |
| Q2 2025 | Aug 12, 2025 | −27.9% |
| Quarter to Mar 31, 2025 | May 28, 2025 | +2.6% |
| Q4 2024 | Mar 24, 2025 | −2.7% |
| Q3 2024 | Nov 27, 2024 | +5.2% |
| Q2 2024 | Jul 25, 2024 | −7.9% |
| Q1 2024 | May 29, 2024 | +2.6% |
| Q4 2023 | Mar 29, 2024 | +15.7% |
| Q3 2023 | Nov 29, 2023 | +19.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 31, 2023 · After close | +1.5% |
| Q1 2023 | Apr 28, 2023 · Before open | +1.6% |
| Q4 2022 | Mar 28, 2023 · After close | +4.1% |
| Q3 2022 | Nov 3, 2022 · After close | +0.8% |
| Q2 2022 | Aug 30, 2022 · After close | −0.7% |
| Q1 2022 | Apr 25, 2022 · After close | +1.9% |
| Q4 2021 | Mar 31, 2022 · Before open | −4.4% |
| Q3 2021 | Dec 1, 2021 | −5.1% |
| Q2 2021 | Aug 25, 2021 · After close | −1.2% |
| Q1 2021 | Jun 2, 2021 | −2.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 34 slides | September 2026 |
| Investor Presentation (July 2023) | Investor deck | 31 slides | Jul 7, 2023 |
| Investor Presentation (January 2022) | Investor deck | 19 slides | Jan 12, 2022 |
IPO
Priced at US$19.00 an ADS on Feb 8, 2021.
- Price
- US$19.00 an ADS
- ADSs offered
- 7,354,000 American depositary shares
- Offering size
- US$139.7 million
- Underwriters' option
- Up to 1,103,100 more ADSs
- Listing
- ADAG on the Nasdaq Global Market
- Underwriters
- Goldman Sachs (Asia) L.L.C., Morgan Stanley, Jefferies, China Renaissance · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 22, 2020 |
| Filed publicly | Jan 19, 2021 |
| Amended 3 times | Newest Feb 5, 2021 |
| Shares registered with an exchange | Feb 3, 2021 |
| Declared effective by the SEC | Feb 8, 2021 |
| Final prospectus, with the price | Feb 10, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 10, 2021 |
| EFFECT · Notice that a registration is effective | Feb 8, 2021 |
| CERT · Exchange's certificate of listing | Feb 8, 2021 |
| F-1/A · Registration statement, amended | Feb 5, 2021 |
| CORRESP · Letter to the SEC | Feb 4, 2021 |
| CORRESP · Letter to the SEC | Feb 4, 2021 |
| CORRESP · Letter to the SEC | Feb 4, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 3, 2021 |
| CORRESP · Letter to the SEC | Feb 3, 2021 |
| F-1/A · Registration statement, amended | Feb 3, 2021 |
All 28 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| F-1/A · Registration statement, amended | Feb 1, 2021 |
| UPLOAD · Letter from the SEC | Jan 28, 2021 |
| CORRESP · Letter to the SEC | Jan 19, 2021 |
| F-1 · Registration statement | Jan 19, 2021 |
| UPLOAD · Letter from the SEC | Dec 9, 2020 |
| DRSLTR · Letter to the SEC with a draft | Nov 24, 2020 |
| DRS/A · Draft registration statement, amended | Nov 24, 2020 |
| UPLOAD · Letter from the SEC | Nov 12, 2020 |
| DRSLTR · Letter to the SEC with a draft | Oct 27, 2020 |
| DRS/A · Draft registration statement, amended | Oct 27, 2020 |
| UPLOAD · Letter from the SEC | Oct 20, 2020 |
| DRSLTR · Letter to the SEC with a draft | Sep 22, 2020 |
| DRS · Draft registration statement | Sep 22, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 10, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.67M | 103.2K | 18.1M | 9.29M | 10.2M | 700.9K | 480.0K | 1.51M |
| Cost of revenue | 582.6K | 926.2K | ||||||
| Gross profit | 7.67M | -823.0K | 18.1M | 9.29M | 10.2M | 480.0K | 480.0K | 1.51M |
| Research and development | 22.0M | 28.8M | 36.6M | 81.3M | 68.1M | 33.5M | 16.2M | 16.1M |
| Selling, general and administrative | 7.08M | 7.27M | 8.67M | 11.9M | 14.4M | 3.44M | 3.44M | 2.77M |
| Operating income | -21.4M | -36.0M | -23.7M | -83.9M | -72.4M | -43.2M | -19.2M | -17.3M |
| Depreciation and amortization | 438.9K | 723.0K | 980.1K | 1.15M | 1.13M | 858.4K | 816.7K | 909.0K |
| EBITDA | -21.0M | -35.2M | -22.7M | -82.8M | -71.2M | -42.3M | -18.4M | -16.4M |
| Interest expense | 463.1K | 851.9K | 1.11M | 693.3K | 363.8K | 202.2K | 138.1K | 91.1K |
| Income before tax | -17.9M | -33.4M | -17.3M | -13.5M | -17.0M | -42.4M | -16.4M | -15.3M |
| Income tax | -297.9K | -17.6K | 1.69M | 459.1K | 1.70M | 3.16K | 861.6K | -547.0K |
| Net income | -17.6M | -33.4M | -18.9M | -80.0M | -73.2M | -42.4M | -16.4M | -15.3M |
| Earnings per share, basic | -0.30 | -0.59 | -0.35 | -1.48 | -1.46 | -2.67 | -1.10 | -0.94 |
| Earnings per share, diluted | -0.30 | -0.59 | -0.35 | -0.31 | -1.46 | -2.67 | -1.10 | -0.94 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 74.5M | 85.2M | 109.9M | 143.8M | 174.4M | 75.2M | 92.5M | 16.1M |
| Short-term investments | 0 | 0 | 0 | 0 | 8.00M | 33.0M | ||
| Receivables | 17.3K | 8.31K | 222.0K | 619.4K | 3.00M | 132.4K | 480.0K | 1.43M |
| Inventory | 1 | 1 | ||||||
| Current assets | 77.4M | 87.8M | 113.4M | 149.3M | 186.0M | 79.1M | 103.9M | 51.8M |
| Property, plant and equipment | 717.4K | 1.13M | 1.84M | 2.78M | 3.49M | 2.07M | 1.88M | 2.55M |
| Total assets | 78.3M | 89.3M | 115.7M | 152.4M | 189.5M | 84.3M | 105.9M | 54.4M |
| Accounts payable | 2.88M | 4.24M | 3.09M | 3.67M | 3.32M | 1.81M | 712.7K | 559.0K |
| Current liabilities | 25.2M | 38.2M | 31.5M | 55.1M | 29.8M | 16.1M | 7.18M | 10.3M |
| Long-term debt | 1.14M | 417.3K | 13.5M | 14.1M | 2.99M | 2.97M | 1.52M | |
| Total debt | 6.12M | 18.2M | 21.9M | 27.8M | 7.49M | 7.98M | 2.56M | 2.33M |
| Total liabilities | 26.4M | 38.7M | 45.2M | 69.3M | 33.0M | 19.2M | 8.70M | 95.4M |
| Shareholders' equity | 35.3M | 50.5M | 70.6M | 83.1M | 156.6M | -89.4M | -57.0M | -41.0M |
| Shares outstanding | 59.2M | 58.9M | 55.1M | 54.1M | 54.6M | 16.6M | 15.2M | 54.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.7M | -29.7M | -28.5M | -48.6M | -43.4M | -28.5M | -18.2M | -14.3M |
| Capital spending | -17.1K | -33.6K | -85.0K | -690.9K | -2.51M | -935.2K | -151.8K | -514.7K |
| Free cash flow | -15.7M | -29.7M | -28.5M | -49.3M | -45.9M | -29.5M | -18.3M | -14.8M |
| Cash from investing | 476.8K | 1.11M | -77.4K | -686.0K | -2.51M | 7.07M | 24.9M | -29.5M |
| Cash from financing | 4.45M | 3.77M | -5.37M | 17.8M | 145.4M | 4.44M | 69.7M | 51.1M |
| Dividends paid | -322.8K | -4.61M | ||||||
| Share buybacks | 0 | 0 | -3.98M | -2.36M | 0 | |||
| Change in cash | -10.7M | -24.7M | -33.8M | -30.6M | 99.2M | -17.4M | 76.5M | 7.32M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Sep 25, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 22, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Sep 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
All 194 filings
Cap table
Built by 6ix from Adagene, Inc.’s releases
- Common shares
- 67,143,344
- Fully diluted
- 67,143,344
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 67,143,344 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 67,143,344 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cuong Do Other companies: BioVie Inc. (President & Chief Executive Officer · Since at least Jul 1, 2018); Spark I Acquisition Corp. (Director · Oct 5, 2023 – Oct 5, 2023 · Past); Merck & Company, Inc. (EVP & Chief Strategy Officer · Oct 3, 2011 – May 6, 2013 · Past); TE Connectivity plc (SVP, Corp. Strategy & Bus. Dev · Jun 16, 2010 – Sep 15, 2011 · Past) | Independent Director · Since at least Mar 18, 2026 |
| Alexander Goergen | Vice President, Head of Business Development · Since at least Nov 5, 2026 |
| Andy Cheung | Independent Director · Since at least Nov 4, 2026 |
| Guizhong Liu | Senior Vice President of Early Drug Discovery · Since at least Nov 5, 2026 |
| Jiping Zha | Executive Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Kristine She | Senior Vice President, Head of Clinical Operations · Since at least Nov 5, 2026 |
| Ling Zhou | Executive Director, Head of Human Resources · Since at least Mar 18, 2026 |
| Li Zhu | Director · Since at least Mar 18, 2026 |
| Man Kin Tam | Chief Financial Officer · Since at least Nov 5, 2026 |
| Mickael Chane-Du | Chief Strategy Officer · Since at least Mar 18, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Peter Luo | Chairman of the Board of Directors · Since at least Mar 18, 2026 |
| Qinghai Zhao | Chief Manufacturing Officer · Since at least Nov 5, 2026 |
| Songmao Zheng | Senior Vice President of Clinical Pharmacology and Quantitative Sciences · Since at least Nov 5, 2026 |
| Ulf Grawunder | Independent Director · Since at least Mar 17, 2026 |
| Wenlin Zeng | Vice President of Early Stage CMC · Since at least Nov 5, 2026 |
| Yan Li | Senior Vice President, Bioinformatics and Information Technology · Since at least Nov 5, 2026 |
| Zhu Li | Independent Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Adagene, Inc.